Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Joachim G S Veit Yves Poumay D Mendes Joanna M Kreitinger L Walker A Paquet C Menigot Francesca Zolezzi Amy S Paller P Diaz

Published in: Skin health and disease (2021)

These preliminary studies suggest that DX308 is an efficacious topical therapeutic with a favourable metabolic and safety profiles. DX308 may present an improved therapeutic alternative for the treatment of keratinization disorders and other retinoid-responsive skin ailments.

Keyphrases

stem cells
wound healing
combination therapy
drug delivery
mesenchymal stem cells
cell therapy
case control